Search form

Advanced Search
 

prostate cancer

Michael Johnson Thumb
Jan 26 2017

Michael Johnson, Co-founder of Visikol Inc., was named to Forbes' ‘30 Under 30’ list for science. 

Jul 16 2014

The new findings from Rutgers Cancer Institute of New Jersey indicate survival benefit is lacking for older patients given hormone treatment as a sole therapy.

Hatem E. Sabaawy
Oct 28 2013

Research from Rutgers Cancer Institute of New Jersey demonstrates that using zebrafish to identify self-renewing tumor stem cells in prostate cancers may be more beneficial than using traditional experimental models when aiming to predict response